Olanzapine
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Schizoaffective Disorder
Trial Timeline
Sep 1, 2003 → Nov 1, 2005
NCT ID
NCT00100776About Olanzapine
Olanzapine is a approved stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00100776. Target conditions include Schizophrenia, Schizoaffective Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00982020 | Approved | Completed |
| NCT00618748 | Phase 3 | Completed |
| NCT00568672 | Phase 3 | Withdrawn |
| NCT00510211 | Pre-clinical | Completed |
| NCT00290121 | Approved | Completed |
| NCT00275301 | Pre-clinical | Completed |
| NCT00259272 | Phase 3 | Completed |
| NCT00113594 | Phase 3 | Completed |
| NCT00191997 | Approved | Completed |
| NCT00088036 | Phase 3 | Completed |
| NCT00100776 | Approved | Completed |
| NCT00191828 | Approved | Completed |
| NCT00194064 | Phase 3 | Terminated |
| NCT00036088 | Approved | Completed |
| NCT00260962 | Phase 2 | Completed |
| NCT00182507 | Approved | Completed |
Competing Products
20 competing products in Schizophrenia